Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Response to Self-improvement: Embracing a Development Outlook - 2Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- 3Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- 4Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- 57 Fast Approaches to Let loose Space on Your Telephone in a flash
- Which '80s Film Actually Holds Up Today?
- The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- How to watch Dick Clark’s New Year’s Rockin’ Eve with Ryan Seacrest: Start time, TV channel, performers and more
- 10 Hints for a Fruitful New employee screening
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- Tremendous Spelunking: Cool Caverns All over the Planet
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
